Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year Low at $25.84

Shares of Royalty Pharma plc (NASDAQ:RPRX) reached a new 52-week low on Tuesday . The stock traded as low as $25.84 and last traded at $25.92, with a volume of 1225141 shares. The stock had previously closed at $26.19.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Bank of America cut their price target on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, April 12th. UBS Group cut shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective for the company. in a research note on Monday, June 3rd. Finally, StockNews.com downgraded shares of Royalty Pharma from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Royalty Pharma has a consensus rating of “Moderate Buy” and an average price target of $43.00.

Royalty Pharma Price Performance

The company has a debt-to-equity ratio of 0.62, a quick ratio of 12.52 and a current ratio of 12.52. The firm has a market capitalization of $15.49 billion, a P/E ratio of 19.34, a price-to-earnings-growth ratio of 3.38 and a beta of 0.46. The business has a 50 day simple moving average of $27.25 and a two-hundred day simple moving average of $28.45.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.96 by $0.02. Royalty Pharma had a return on equity of 22.94% and a net margin of 35.70%. The firm had revenue of $568.00 million for the quarter, compared to analyst estimates of $671.45 million. During the same period in the prior year, the company earned $1.60 EPS. On average, sell-side analysts expect that Royalty Pharma plc will post 4.03 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 17th were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 3.24%. The ex-dividend date of this dividend was Thursday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is currently 62.69%.

Institutional Investors Weigh In On Royalty Pharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Fidelis Capital Partners LLC purchased a new position in shares of Royalty Pharma in the 1st quarter valued at approximately $46,000. GAMMA Investing LLC lifted its stake in shares of Royalty Pharma by 172.5% in the 1st quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 1,037 shares during the period. Allworth Financial LP increased its position in Royalty Pharma by 76.7% during the 4th quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 731 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in Royalty Pharma by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 802 shares in the last quarter. Finally, Lindbrook Capital LLC increased its position in Royalty Pharma by 485.2% during the 4th quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 1,999 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.